Search

Your search keyword '"Wood-Siverio, C"' showing total 3 results
Start Over Author "Wood-Siverio, C" Topic aging
3 results on '"Wood-Siverio, C"'

1. Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease

Author

Kelly, VE, Johnson, CO, McGough, EL, Shumway-Cook, A, Horak, FB, Chung, KA, Espay, AJ, Revilla, FJ, Devoto, J, Wood-Siverio, C, Factor, SA, Cholerton, B, Edwards, KL, Peterson, AL, Quinn, JF, Montine, TJ, Zabetian, CP, and Leverenz, JB

Subjects
Neurosciences, Parkinson's Disease, Brain Disorders, Mental Health, Neurodegenerative, Behavioral and Social Science, Aging, Neurological, Mental health, Aged, Cognition, Cognition Disorders, Cross-Sectional Studies, Female, Gait Disorders, Neurologic, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease, Postural Balance, Executive function, Balance, Gait, Freezing of gait, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

IntroductionResearch suggests an association between global cognition and postural instability/gait disturbance (PIGD) in Parkinson disease (PD), but the relationship between specific cognitive domains and PIGD symptoms is not clear. This study examined the association of cognition (global and specific cognitive domains) with PIGD symptoms in a large, well-characterized sample of individuals with PD.MethodsCognitive function was measured with a detailed neuropsychological assessment, including global cognition, executive function, memory, visuospatial function, and language. PIGD symptoms were measured using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, Motor Examination subscale. Multiple linear regression analyses were performed to assess the relationship between cognition and PIGD symptoms with models adjusting for age, sex, education, enrollment site, disease duration, and motor symptom severity.ResultsThe analysis included 783 participants, with mean (standard deviation) age of 67.3 (9.7) years and median (interquartile range) MDS-UPDRS Motor Subscale score of 26 (17, 35). Deficits in global cognition, executive function, memory, and phonemic fluency were associated with more severe PIGD symptoms. Deficits in executive function were associated with impairments in gait, freezing, and postural stability, while visuospatial impairments were associated only with more severe freezing, and poorer memory function was associated only with greater postural instability.DiscussionWhile impairments in global cognition and aspects of executive functioning were associated with more severe PIGD symptoms, specific cognitive domains were differentially related to distinct PIGD components, suggesting the presence of multiple neural pathways contributing to associations between cognition and PIGD symptoms in persons with PD.

Published
2015

2. Cognitive profile of LRRK2-related Parkinson's disease

Author

Srivatsal, S, Cholerton, B, Leverenz, JB, Wszolek, ZK, Uitti, RJ, Dickson, DW, Weintraub, D, Trojanowski, JQ, Van Deerlin, VM, Quinn, JF, Chung, KA, Peterson, AL, Factor, SA, Wood-Siverio, C, Goldman, JG, Stebbins, GT, Bernard, B, Ritz, B, Rausch, R, Espay, AJ, Revilla, FJ, Devoto, J, Rosenthal, LS, Dawson, TM, Albert, MS, Mata, IF, Hu, SC, Montine, KS, Johnson, C, Montine, TJ, Edwards, KL, Zhang, J, and Zabetian, CP

Subjects
Adult, Male, cognition, neuropsychological tests, Aging, Parkinson's disease, Clinical Sciences, Neuropsychological Tests, Protein Serine-Threonine Kinases, Neurodegenerative, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Article, working memory, Cohort Studies, 80 and over, Genetics, Acquired Cognitive Impairment, Humans, 2.1 Biological and endogenous factors, Genetic Testing, Aetiology, Aged, Aged, 80 and over, Neurology & Neurosurgery, Neurosciences, Parkinson Disease, LRRK2, Human Movement and Sports Sciences, Middle Aged, Brain Disorders, nervous system diseases, Cross-Sectional Studies, Good Health and Well Being, Mutation, Neurological, Cognitive Sciences, Female, Dementia, Cognition Disorders, Mental Status Schedule
Abstract

© 2015 International Parkinson and Movement Disorder Society. Background: Increasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2-related PD is not well-characterized. Methods: A cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models. Results: LRRK2 mutation carriers (n=29) demonstrated better performance on the Mini Mental State Examination (P=0.03) and the Letter-Number Sequencing Test (P=0.005). A smaller proportion of LRRK2 carriers were demented (P=0.03). Conclusions: Our cross-sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2-related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline.

Published
2015

3. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study

Author

Paulsen, J. S., Johnson, H. J., Aylward, E. H., Ross, C. A., Williams, J. K., Nance, M. A., Erwin, C. J., Westervelt, H. J., Harrington, D. L., Bockholt, H. J., Zhang, Y., McCusker, E. A., Chiu, E. M., Panegyres, P. K., Cross, S., Ryan, P., Epping, E. A., Preston, J., Goh, A., Antonopoulos, S., Loi, S., Raymond, L., Decolongon, J., Fan, M., Coleman, A., Mallone, W. M., Suter, G., Varvaris, M., Yoritomo, N., Griffith, J., Loy, C., Gunn, D., Guttman, M., Sheinberg, A., Law, A., Quaid, K., Wesson, M., Wojcieszek, J., Perlmutter, J., Barton, S., Smith, S., Barker, R. A., Mason, S., Guzman, N. V., Perlman, S., Clemente, B., Jones, R., Wood-Siverio, C., Factor, S. A., Samii, A., Macaraeg, A., Lee, J., Tedesco, M., Maxwell, B., Kumar, R., Erickson, D., Nickels, B., Marshall, F., Chesire, A., Wodarski, M., Hickey, C., Geschwind, M. D., Sha, S., Satris, G., Ahmed, A., Reece, C., Bura, A., Mourany, L., Pillai, J., Mazzoni, P., Marder, K., Wasserman, P., Craufurd, D., Bek, J., Howard, E., Warner, T., Burrows, M., Orth, M., Süßmuth, S., Barth, K., Trautmann, S., Schwenk, D., Eschenbach, C., Wheelock, V., Kjer, L., Martin, A., Farias, S., Miedzybrodzka, Z., Rae, D., D'Alessandro, M., Suchowersky, O., Chua, P., Komiti, A., Rosas, D., Rosser, Anne Elizabeth, Price, K., Hunt, S., Jankovic, J., Ondo, W., Martin, W., King, P., Wieler, M., Sran, S., de Yébenes, J. G., Dubinsky, R., and PREDICT-HD Investigators and Coordinators of the Huntington Study Group

Subjects
Aging, Pediatrics, medicine.medical_specialty, PREDICT-HD, Cognitive Neuroscience, Disease, Q1, Developmental psychology, lcsh:RC321-571, outcome measures, medicine, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Original Research, clinical trials, business.industry, Outcome measures, premanifest, Cognition, R1, 3. Good health, Natural history, Clinical trial, Huntington Disease, Cohort, Neurodegenerative disorders, Biomarker (medicine), Observational study, business, Neuroscience, Natural History
Abstract

There is growing consensus that intervention and treatment of Huntington disease (HD) should occur at the earliest stage possible. Various early-intervention methods for this fatal neurodegenerative disease have been identified, but preventive clinical trials for HD are limited by a lack of knowledge of the natural history of the disease and a dearth of appropriate outcome measures. Objectives of the current study are to document the natural history of premanifest HD progression in the largest cohort ever studied and to develop a battery of imaging and clinical markers of premanifest HD progression that can be used as outcome measures in preventive clinical trials. Neurobiological predictors of Huntington's disease is a 32-site, international, observational study of premanifest HD, with annual examination of 1013 participants with premanifest HD and 301 gene-expansion negative controls between 2001 and 2012. Findings document 39 variables representing imaging, motor, cognitive, functional, and psychiatric domains, showing different rates of decline between premanifest HD and controls. Required sample size and models of premanifest HD are presented to inform future design of clinical and preclinical research. Preventive clinical trials in premanifest HD with participants who have a medium or high probability of motor onset are calculated to be as resource-effective as those conducted in diagnosed HD and could interrupt disease 7-12 years earlier. Methods and measures for preventive clinical trials in premanifest HD more than a dozen years from motor onset are also feasible. These findings represent the most thorough documentation of a clinical battery for experimental therapeutics in stages of premanifest HD, the time period for which effective intervention may provide the most positive possible outcome for patients and their families affected by this devastating disease.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results